NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Nanobots Therapeutics

Nanobots Therapeutics

Private
BarcelonaHealthcare & Life Scienceshttps://www.nanobotstx.com/

Last Round

Seed

Dec 18, 2024

Est. Valuation

$7.81M

Total Funding Raised

$2.5M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Nanobots Therapeutics is a biotechnology company developing a nanorobot-based drug delivery platform, MotionTx, to deliver treatments directly to target tissues, with an initial focus on bladder cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

drug delivery platformnanoroboticsnanomedicinenanobotstargeted therapysolid tumor treatmentbiotechprecision medicinebiotechnologydrug developmentmedical devicespre-clinical researchbiocompatible materialsoncologypharma licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nanobots Therapeutics Comparables

Compare Nanobots Therapeutics with similar companies based on industry and business-model similarity.

Nanobots Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NanoDrug Delivery GmbH
81%
Bionaut Labs
77%
Onselex Pharmaceuticals
75%

Nanobots Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedDec 18, 2024
Pre SeedSep 22, 2023

Key People

Founding team and executive leadership

Andres G. Fernandez

Chief Development Officer (CDO), Member Of The Management Board, Co-Founder - Drug Development Advisor

Founding Team

Samuel Sánchez Ordóñez

Founder, Interim CEO And CSO, Chief Scientific Officer

Founding Team

Marta Soler Grima

COO

Executive Team

Nanobots Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 6, 12x the trailing average.

  • Dec 18, 2024

    $2M round from BStartup Health and others.

Nanobots Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nanobots Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nanobots Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBarcelona
Employee Range14
Year Founded2023
Last FundingDec 18, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.